Determinants of drug metabolism in early neonatal life

Current Clinical Pharmacology

Volumn 2, Issue 1, 2007, Pages 23-29

  Allegaert, Karel ^a   van den Anker, John N ^b,c,d   Naulaers, Gunnar ^a   de Hoon, Jan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Cytochrome P450 iso enzymes; Metabolism; Ontogeny; Paracetamol; Tramadol; Uridine diphosphate glucuronosyltransferase iso enzymes

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE; CODEINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A7; DRUG METABOLITE; ESTERASE; GLUCURONOSYLTRANSFERASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; PARACETAMOL; PARACETAMOL GLUCURONIDE; PARACETAMOL SULFATE; PROPACETAMOL; SEROTONIN UPTAKE INHIBITOR; TRAMADOL;

AGE; ANALGESIC ACTIVITY; COMORBIDITY; DRUG DISPOSITION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG URINE LEVEL; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HEREDITY; HUMAN; LIVER METABOLISM; MULTIVARIATE ANALYSIS; NEWBORN PERIOD; NONHUMAN; PAIN; PHARMACODYNAMICS; PHENOTYPIC VARIATION; PREDICTION; PRIORITY JOURNAL; REVIEW;

ACETAMINOPHEN; AGE FACTORS; ANALGESICS; HUMANS; INFANT; INFANT, NEWBORN; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TRAMADOL;

EID: 34248146195     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488407779422294     Document Type: Review

References (46)

1. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kaufman RE. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-67.
2. Van den Anker JN. Pharmacokinetics and renal function in the preterm infant. Acta Paediatr 1996; 85:1393-9.
3. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: Part 1. Clin Pharmacokinet 2002; 41: 959-98.
4. Allegaert K, Anderson BJ, Cossey V, Holford NH. Limited predictability of amikacin clearance in extremely preterm neonates at birth. Br J Clin Pharmacol 2006;61: 39-48.
5. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: Phase I oxidative enzymes. J Pharmacol Exp Ther 2002; 300: 355-60.
6. McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 2002; 300: 361-6.
7. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999; 36: 439-52.
8. Rane A. Phenotyping of drug metabolism in infants and children: potentials and problems. Pediatrics 1999; 104: 640-3.
9. Ring JA, Ghabrial H, Ching MS, et al. Fetal hepatic drug elimination. Pharmacol Ther 1999;84: 429-45.
10. Ladona MG, Lindstrom B, Thyr C, Dun-Ren P, Rane A. Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man. Br J Clin Pharmacol 1991; 32: 295-302.
11. Capparelli EV, Mirochnick M, Dankner WM, et al. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr 2003; 142: 47-52.
12. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-37.
13. Wells PG, MacKenzie PI, Chowdhury JR, et al. Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab Dispos 2004; 32: 281-90.
14. Lynn A, Nespeca MK, Bratton SL, Strauss SG, Shen DD. Clearance of morphine in postoperative infants during intravenous infusion: the influence of age and surgery. Anesth Analg 1998; 86: 958-63.
15. Carcillo JA, Doughty L, Kofos D, et al. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med 2003; 29: 980-4.
16. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver - evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997; 247: 625-34.
17. Treluyer JM, Jacqz-Aigrain E, Alvarez F, Cresteil T. Expression of CYP2D6 in developing human liver. Eur J Biochem 1991; 202: 583-8.
18. Jacqz-Aigrain E, Cresteil T. Cytochrome P450-dependent metabolism of dextromethorphan: fetal and adult studies. Dev Pharmacol Ther 1992; 18: 161-8.
19. Allegaert K, Anderson B, Verbesselt R, et al. Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P4502D6 activity. Br J Anaesth 2005; 95: 231-9.
20. Allegaert K, van den Anker JN, Debeer A, et al. Maturational changes in the activity of in vivo activity of CYP3A4 in the first months of life. Int J Clin Pharmac Ther 2006; 44: 303-8.
21. Allegaert K, van den Anker JN, Verbesselt R, et al. O-demethylation of tramadol in the first months of life. Eur J Clin Pharmacol 2005; 61: 837-42.
22. Pedersen RS, Damkier P, Brosen K. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther 2005; 77: 458-67.
23. Johnson TN. Different pharmacokinetics of tramadol in mothers treated for labour pain and in their neonates. Towards an increased knowledge of paediatric clinical pharmacology. Eur J Clin Pharmacol 2005; 61: 929-30.
24. Depre M, van Hecken A, Verbesselt R, et al. Tolerance and pharmacokinetics of propacetamol, a paracetamol formulation for intravenous use. Fundam Clin Pharmacol 1992; 6:259-62.
25. Anderson B, Pons G, Autret E, Allegaert K, Boccard E. Paediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Pediatr Anesth 2005; 15: 282-92.
26. De Peyster A, Willis WO, Liebhaber M. Cholinesterase activity in pregnant women and newborns. J Toxicol Clin Toxicol 1994; 32: 683-96.
27. Van der Marel CD, Anderson BJ, Van Lingen RA, et al. Paracetamol and metabolite pharmacokinetics in infants. Eur J Clin Pharmacol 2003; 59: 243-51.
28. Allegaert K, de Hoon J, Verbesselt R, Vanhole C, Devlieger H, Tibboel D. Intra- and interindividual variability of glucuronidation of paracetamol during repeated administration in neonates. Acta Paediatr 2005; 94: 1273-9.
29. Ghanem CI, Ruiz ML, Villanueva SS, et al. Shift from biliary to urinary elimination of acetaminophen glucuronide in acetaminophen petreated rats. J Pharmacol Exp Ther 2005; 315: 987-95.
30. Allegaert K, Tibboel D. Comments on 'shift from biliary to urinary elimination of acetaminophen-glucuronide in acetaminophen-pretreated rats. J Pharmacol Exp Ther 2006; 316: 966-7.
31. Krumbiegel P, Domke S, Morseburg B, Boehm G, Braun W. Maturation of hepatosomal mono-oxygenation and glucuronidation activities in pre- and full-term infants as studied using the [15N]methacetin urine test. Acta Paediatr 1997; 86: 1236-40.
32. Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NH. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth 2004; 92: 208-17.
33. Kearns GL, Robinson PK, Wilson JT, et al. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. Clin Pharmacol Ther 2003; 74: 312-25.
34. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A. Ontogeny and drug disposition. Clin Pharmacokinet 1999; 37: 485-505.
35. Blake MJ, Abdel-Rahmand M, Pearce RE, et al. Effect of diet on the ontogeny of caffeine and dextromethorphan metabolism. Clin Pharmacol Therap 2006; 79: P6.
36. Veereman-Wauters G, Staelens S, Van Den Driessche ML, et al. Gastric emptying in newborns fed an intact protein formula, a partially and an extensively hydrolysed formula. Gastroenterology 2004; 126: A67.
37. Jager-Roman E, Doyle PE, Baird-Lambert J, Cvejic M, Buchanan N. Pharmacokinetics and tissue distribution of metronidazole in the new born infant. J Pediatr 1982; 100: 651-4.
38. Baird-Lambert J, Doyle PE, Thomas D, Jager-Roman E, Cvejic M, Buchanan N. Theophylline metabolism in preterm neonates during the first weeks of life. Dev Pharmacol Ther 1984; 7:239-44.
39. Leeder JS. Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. DDT 2004; 9: 567-73.
40. Leeder JS, Gotshall RR, Gaedigk A, Adcock K, Wilson JT, Kearns GL. Acquisition of functional CYP2D6 and CYP3A4 activities in vivo in the first year of life. Drug Metab Rev 2000; 32: A281.
41. Abdel-Rahman SM, Leeder JS, Wilson JT, et al. Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol 2002; 42: 24-9.
42. Kapur G, Mattoo T, Aranda JV. Pharmacogenomics and renal drug disposition in the newborn. Semin Perinatol 2004; 28: 32-40.
43. Bjorkman S. Prediction of cytochrome P450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods ? Clin Pharmacokinet 2006; 45: 1-11.
44. Anderson BJ, Hansen TG. Getting the best from pediatric pharmacokinetic data. Paediatr Anaesth 2004; 14: 713-714.
45. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 2006; (online available).
46. Van den Anker J. Managing drugs safely. Semin Fetal Neonatal Med 2005; 10: 73-81.